An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Angel
A
Rubin
Marina
M
Berenguer
D000998:Antiviral Agents / Q000008:administration & dosage* / Q000191:economics; D017046:Cost Savings; D003661:Decision Support Techniques; D018450:Disease Progression; D004334:Drug Administration Schedule; D016527:Drug Costs; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control / Q000821:virology; D006085:Graft Survival / Q000187:drug effects; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000601:surgery; D006801:Humans; D007372:Interferons / Q000008:administration & dosage* / Q000191:economics; D008103:Liver Cirrhosis / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000601:surgery / Q000821:virology; D016031:Liver Transplantation / Q000191:economics; D008390:Markov Chains; D018579:Patient Selection; D019057:Quality-Adjusted Life Years; D012008:Recurrence; D012254:Ribavirin / Q000008:administration & dosage* / Q000191:economics; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D019562:Viral Load
D000998:Antiviral Agents; D012254:Ribavirin; D007372:Interferons